Current Report Filing (8-k)
December 19 2019 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December
17, 2019
Catabasis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
001-37467
|
|
26-3687168
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
100 High Street
28th Floor
Boston, Massachusetts
|
|
02110
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (617) 349-1971
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, Massachusetts
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.001 par value per share
|
|
CATB
|
|
The Nasdaq Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company x
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 17, 2019, the Board of Directors
(the “Board”) of Catabasis Pharmaceuticals, Inc. (the “Company”) appointed Noah Clauser, the Company’s
Vice President, Finance as the Company’s principal financial officer, effective immediately. Mr. Clauser, age 46, has served
as the Company’s Vice President, Finance and led the Company’s finance and operations functions since August 2017.
Previously, he served as Senior Director, Finance and Controller of the Company from January 2016 to August 2017 and as Controller
of the Company from April 2011 to December 2015. Mr. Clauser is a licensed Certified Public Accountant in Massachusetts and holds
an M.S. in Accounting and a B.S. in Management from the University of Massachusetts at Boston.
Upon Mr. Clauser’s appointment, Dr.
Jill C. Milne, the Company’s President and Chief Executive Officer, voluntarily resigned her position as the Company’s
principal financial officer. Dr. Milne will continue to maintain her leadership position as President and Chief Executive Officer
and her directorship role on the Company Board.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CATABASIS PHARMACEUTICALS, INC.
|
|
|
|
Date: December 19, 2019
|
By:
|
/s/ Jill C. Milne
|
|
|
Jill C. Milne
|
|
|
President and Chief Executive Officer
|
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024